StreetInsider.com News Articles

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Thu, 15 Oct 2026 15:57:00 -0400

si-local-file:///var/storage/secattach/20261015/27193231.html

Cantor Fitzgerald Resumes Arcutis Biotherapeutics Inc. (ARQT) at Overweight

Thu, 15 Oct 2026 06:34:10 -0400

Cantor Fitzgerald resumes coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) with a Overweight rating and a price target of $48.00.

For an analyst ratings summary and ratings history on Arcutis Biotherapeutics Inc. click here. For more ratings news on Arcutis Biotherapeutics Inc. click here.

Shares of Arcutis Biotherapeutics Inc. closed at $26.41 yesterday.

Arcutis presents Zoryve and corticosteroid data at dermatology meetings

Fri, 09 Oct 2026 08:01:06 -0400

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) presented clinical and real-world data on its Zoryve (roflumilast) portfolio at two dermatology conferences: the 35th European Academy of Dermatology and Venereology Congress, held Sept. 30–Oct. 3 in Vienna, Austria, and the Fall Clinical Dermatology Conference, held Oct. 8–11 in Las Vegas, Nevada.

Among the presentations, data from the Phase 2 INTEGUMENT-INFANT study evaluated investigational once-daily Zoryve cream 0.05% in 101 infants aged 3 to less than 24 months with atopic dermatitis. Of the 96 infants who completed four weeks of treatment, 34.4% achieved Validated Investigator Global Assessment success, defined as a score of clear or

Arcutis presents Zoryve and corticosteroid data at dermatology meetings

Fri, 09 Oct 2026 08:01:06 -0400

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Fri, 09 Oct 2026 08:00:00 -0400

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited
New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasis
Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis
Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions

WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT),

Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical

Fri, 09 Oct 2026 08:00:00 -0400

Presentation of data from the INTEGUMENT-INFANT trial of investigational ZORYVE cream 0.05% in infants ages 3 to <24 months, where treatment options remain limited
New analyses from the ARRECTOR and DERMIS-1/2 trials further demonstrate ZORYVE's efficacy and symptom improvements across the body in individuals with psoriasis
Additional data from collaborative research reinforce the inflammatory pathway and barrier impairment involved in seborrheic dermatitis
Real-world research examines the role long-term topical corticosteroid use plays in the care of adults and children with chronic inflammatory skin conditions

WESTLAKE VILLAGE, Calif., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT),

Jefferies Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT) ahead of earnings

Thu, 08 Oct 2026 04:23:45 -0400

Jefferies analyst Kambiz Yazdi reiterated a Buy rating and $39.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT).

The analyst comments "For Q3:26, we estimate Zoryve's IMS scripts grew by +8-9% Q/Q (despite summer seasonality), which could translate to $143M+ of sales (vs cons $142M), up from $130M in Q2. (1) Initially launched in Aug 2022, Zoryve (PDE4 roflumilast) is approved for plaque psoriasis (PsO), seborrheic dermatitis (SD), and atopic dermatitis (AD). (2) We are not surprised to see TRx growth moderate Q/Q in Q3 (+8-9% vs +13-14% in Q2), since skin diseases (flares) often improve by themselves during warmer summer

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Tue, 06 Oct 2026 08:19:00 -0400

Newly created award category highlights innovation in prescription skin treatment
ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

WESTLAKE VILLAGE, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.15% was presented with

Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award

Tue, 06 Oct 2026 08:19:00 -0400

Newly created award category highlights innovation in prescription skin treatment
ZORYVE cream 0.15% for mild to moderate atopic dermatitis (eczema) in adults and children 6 years of age and older is first medication to win the award
ZORYVE is the number one prescribed branded topical therapy across three major inflammatory skin conditions combined — eczema, plaque psoriasis, and seborrheic dermatitis

Form SCHEDULE 13G/A Arcutis Biotherapeutics, Filed by: BlackRock, Inc.

Mon, 05 Oct 2026 11:58:00 -0400

si-local-file:///var/storage/secattach/20261005/27147626.html

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:00:00 -0400

WESTLAKE VILLAGE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the grant of an aggregate of 62,500 restricted stock units (RSUs) of Arcutis common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of October 1, 2026, as a material inducement to the new employees in connection with their commencement of employment with

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 16:00:00 -0400

Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

Tue, 29 Sep 2026 09:15:00 -0400

Simone Biles opens up about her experience managing the symptoms of these conditions and encourages long-term control of skin health
Biles’ treatment, ZORYVE^® (roflumilast), is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined — seborrheic dermatitis, eczema, and plaque psoriasis

WESTLAKE VILLAGE, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that World Champion gymnast Simone Biles has partnered with the company to launch its Skin to Believe In awareness

Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options

Tue, 29 Sep 2026 09:15:00 -0400

Simone Biles opens up about her experience managing the symptoms of these conditions and encourages long-term control of skin health
Biles’ treatment, ZORYVE^® (roflumilast), is the #1 prescribed branded topical therapy for three major inflammatory skin conditions combined — seborrheic dermatitis, eczema, and plaque psoriasis

Form 4 Arcutis Biotherapeutics, For: Sep 16 Filed by: Matsuda Masaru

Fri, 18 Sep 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260918/27080738.html

Form 4 Arcutis Biotherapeutics, For: Sep 15 Filed by: Welgus Howard G.

Thu, 17 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260917/27075872.html

Form 144 Arcutis Biotherapeutics, Filed by: Edwards Larry Todd

Wed, 16 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260916/27070337.html

Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.

Tue, 15 Sep 2026 16:04:00 -0400

si-local-file:///var/storage/secattach/20260915/27064808.html

Form 4 Arcutis Biotherapeutics, For: Sep 08 Filed by: Matsuda Masaru

Thu, 10 Sep 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260910/27049737.html

Form 4 Arcutis Biotherapeutics, For: Aug 27 Filed by: Curran Terrie

Fri, 28 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260828/26999238.html

Form 4 Arcutis Biotherapeutics, For: Aug 27 Filed by: Curran Terrie

Fri, 28 Aug 2026 17:40:00 -0400

si-local-file:///var/storage/secattach/20260828/26999238.html

Form 144 Arcutis Biotherapeutics, Filed by: Curran Terrie

Thu, 27 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260827/26989854.html

Form 144 Arcutis Biotherapeutics, Filed by: Curran Terrie

Thu, 27 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260827/26989854.html

Form 4 Arcutis Biotherapeutics, For: Aug 20 Filed by: Curran Terrie

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968360.html

Form 4 Arcutis Biotherapeutics, For: Aug 20 Filed by: Curran Terrie

Mon, 24 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260824/26968360.html